| خلاصه مقاله | Background and Aim : Neurogenic bladder (NGB) and urinary incontinence is a common
embarrassing condition in most of the neurological diseases like as Spinal Cord Injury (SCI). The
prevalence of NGB in patients with SCI is 70% to 84%. Sacral micturition center (S2–S4), pontine
micturition center, and cerebral cortex are responsible for normal urination cycle with facilitation
and inhi¬bition of voiding. In SCI, the lesions between these pathways lead to losing normal
bladder function with manifestation of neurogenic detrusor overactivity that exhibits as uninhibited
bladder contraction and detrusor-sphincter- dyssinergia. Scientists discovered exocytotic vesicular
release of ATP (a purine) as a co-transmitter with acetylcholine from parasympathetic neurons
lead to bladder contraction and voiding reflex in many species. In healthy human the principal
neurotransmitter that initiates muscle contraction is acetylcholine and the role of ATP is minor.
However, in pathological conditions such as neurogenic bladder purinegic components increased
to about 40% and its signaling (the binding of Adenosine triphosphate to its receptors) is
introduced as a new pathway in pathogenesis of many types of NGB. Physiological roles of
purinergic signaling in living bladder and urethra tissues consist of control of
contraction/relaxation of mammalian bladder and relaxation of mammalian urethra. Beside it ATP
plays a role in cell proliferation, differentiation, and death in development and regeneration, as
well as in disease. ATP is a signaling molecule that can act as neurotransmitter and bind with 2
groups of receptors: ionotropic (P2X) and metabotropic (P2Y). P2X and P2Y receptors are present in urothelial cells. In both sensory transduction (by releasing ATP from the umbrella cells) and the
function of bladder the purinergic signaling is play a critical role and is involved in numerous
conditions like as spinal cord injury. The relationship between purinergic signaling and bladder
function is demonstrated by knockout of P2X2/P2X3 in experimental models. After ATP release,
P2X3 receptors on suburothelial sensory nerves initiate the voiding reflex and mediate the
sensation of bladder filling and urgency. The other mechanism of ATP is its effect on suburothelial
interstitial cells/myofibroblasts generating via Ca(2+) transient through gap junctions with sending
signals from urothelium to detrusor muscle. Prolonged purinergic receptors activation leads to
excitotoxicity and neurodegeneration. The results of immunohistochemistry staining of these
receptors showed that P2X2 staining is stronger. And in animals study by using of A-317491 (as
a selective P2X2/P2X3 purinergic receptor antagonist) showed a therapeutic effect in SCI
developed overactive bladder by increasing the intervals of contractions. Beside it Brilliant blue G
(P2X7 receptor antagonist) decrease astrocytes and microglia activation and lead to neuron
protection from excitotoxicity and inflammatory responses. In SCI, ATP release is seen in response
to mechanosensory cholinergic receptor activation followed by P2X7 receptor activation, hence
inhibition of P2X7 receptors can improve SCI recovery by oxidizing ATP and PPADS and
decrease in cell death. Also purinergic signaling affects bladder function in both central and
peripheral (afferent and efferent components) nervous system. Beside it this signaling can altered
smooth muscle of bladder and also urothelial. |